PDCD1 and acute myeloid leukemia: 2017–002194‐18) combining azacitidine and the anti‐PD1 inhibitor nivolumab in relapsed AML patients after allo‐HCT demonstrated an ORR of 25% (12.5% CR(i), 12.5% PR) and a median survival of 15.6 months.85